Your browser doesn't support javascript.
loading
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.
Puzanov, Igor; Ribas, Antoni; Robert, Caroline; Schachter, Jacob; Nyakas, Marta; Daud, Adil; Arance, Ana; Carlino, Matteo S; O'Day, Steven J; Long, Georgina V; Margolin, Kim A; Dummer, Reinhard; Schadendorf, Dirk; Lutzky, Jose; Ascierto, Paolo A; Tarhini, Ahmad; Lin, Jianxin; Mogg, Robin; Homet Moreno, Blanca; Ibrahim, Nageatte; Hamid, Omid.
Afiliación
  • Puzanov I; Roswell Park Cancer Institute, Buffalo, New York.
  • Ribas A; University of California, Los Angeles.
  • Robert C; Gustave Roussy, Paris-Sud University, Villejuif, France.
  • Schachter J; The Chaim Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel.
  • Nyakas M; Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
  • Daud A; Department of Medicine, University of California, San Francisco.
  • Arance A; Hospital Clinic de Barcelona, Barcelona, Spain.
  • Carlino MS; Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Sydney, New South Wales, Australia.
  • O'Day SJ; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
  • Long GV; John Wayne Cancer Institute, Providence St John's Health Center, Santa Monica, California.
  • Margolin KA; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
  • Dummer R; Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.
  • Schadendorf D; City of Hope National Medical Center, Duarte, California.
  • Lutzky J; University Hospital of Zürich, Zürich, Switzerland.
  • Ascierto PA; University Hospital Essen, Essen, Germany.
  • Tarhini A; Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida.
  • Lin J; Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
  • Mogg R; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Homet Moreno B; Merck & Co, Inc, Kenilworth, New Jersey.
  • Ibrahim N; The Bill and Melinda Gates Medical Research Institute, Cambridge, Massachusetts.
  • Hamid O; Merck & Co, Inc, Kenilworth, New Jersey.
JAMA Oncol ; 6(8): 1256-1264, 2020 08 01.
Article en En | MEDLINE | ID: mdl-32672795
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Quinasas de Proteína Quinasa Activadas por Mitógenos / Proteínas Proto-Oncogénicas B-raf / Inhibidores de Proteínas Quinasas / Anticuerpos Monoclonales Humanizados / Antineoplásicos Inmunológicos / Melanoma Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Idioma: En Revista: JAMA Oncol Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Quinasas de Proteína Quinasa Activadas por Mitógenos / Proteínas Proto-Oncogénicas B-raf / Inhibidores de Proteínas Quinasas / Anticuerpos Monoclonales Humanizados / Antineoplásicos Inmunológicos / Melanoma Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Idioma: En Revista: JAMA Oncol Año: 2020 Tipo del documento: Article